Avecho Biotechnology Ltd (AU:AVE) — Market Cap & Net Worth
Market Cap & Net Worth: Avecho Biotechnology Ltd (AVE)
Avecho Biotechnology Ltd (AU:AVE) has a market capitalization of $40.65 Million (AU$57.46 Million) as of June 21, 2026. Listed on the AU stock exchange, this Australia-based company holds position #22697 globally and #831 in its home market, demonstrating a 15.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avecho Biotechnology Ltd's stock price AU$0.02 by its total outstanding shares 3830448257 (3.83 Billion). Review Avecho Biotechnology Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
Avecho Biotechnology Ltd Market Cap History: 2015 to 2026
Avecho Biotechnology Ltd's market capitalization history from 2015 to 2026. Data shows growth from $31.71 Million to $40.65 Million (0.25% CAGR).
Avecho Biotechnology Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avecho Biotechnology Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.71x
Avecho Biotechnology Ltd's market cap is 19.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $76.70 Million | $1.59 Million | -$17.31 Million | 48.30x | N/A |
| 2017 | $48.79 Million | $1.15 Million | -$8.62 Million | 42.42x | N/A |
| 2018 | $13.55 Million | $1.25 Million | -$3.99 Million | 10.82x | N/A |
| 2019 | $10.84 Million | $4.24 Million | $849.96K | 2.56x | 12.75x |
| 2020 | $78.60 Million | $384.63K | -$2.63 Million | 204.35x | N/A |
| 2021 | $40.65 Million | $793.60K | -$3.42 Million | 51.23x | N/A |
| 2022 | $40.65 Million | $1.13 Million | -$2.34 Million | 36.01x | N/A |
| 2023 | $9.49 Million | $473.55K | -$3.44 Million | 20.03x | N/A |
| 2024 | $6.78 Million | $1.13 Million | -$3.12 Million | 5.98x | N/A |
| 2025 | $24.39 Million | $1.24 Million | -$4.42 Million | 19.71x | N/A |
Competitor Companies of AVE by Market Capitalization
Companies near Avecho Biotechnology Ltd in the global market cap rankings as of June 21, 2026.
Key companies related to Avecho Biotechnology Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Avecho Biotechnology Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Avecho Biotechnology Ltd's market cap moved from $31.71 Million to $ 40.65 Million, with a yearly change of 0.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$40.65 Million | +66.67% |
| 2025 | AU$24.39 Million | +260.00% |
| 2024 | AU$6.78 Million | -28.57% |
| 2023 | AU$9.49 Million | -76.67% |
| 2022 | AU$40.65 Million | 0.00% |
| 2021 | AU$40.65 Million | -48.28% |
| 2020 | AU$78.60 Million | +625.00% |
| 2019 | AU$10.84 Million | -20.00% |
| 2018 | AU$13.55 Million | -72.22% |
| 2017 | AU$48.79 Million | -36.40% |
| 2016 | AU$76.70 Million | +141.88% |
| 2015 | AU$31.71 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Avecho Biotechnology Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $40.65 Million USD |
| MoneyControl | $40.65 Million USD |
| MarketWatch | $40.65 Million USD |
| marketcap.company | $40.65 Million USD |
| Reuters | $40.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more